Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR.
Am J Respir Crit Care Med. 2022 Nov 15;206(10):1239-1247. doi: 10.1164/rccm.202204-0734OC.
Am J Respir Crit Care Med. 2022.
PMID: 35771568
Free PMC article.
Clinical Trial.
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE; VX14-661-110 study group.
Flume PA, et al. Among authors: paz diaz h.
Lancet Respir Med. 2021 Jul;9(7):733-746. doi: 10.1016/S2213-2600(20)30510-5. Epub 2021 Feb 10.
Lancet Respir Med. 2021.
PMID: 33581080
Item in Clipboard
A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant.
Sawicki GS, Chilvers M, McNamara J, Naehrlich L, Saunders C, Sermet-Gaudelus I, Wainwright CE, Ahluwalia N, Campbell D, Harris RS, Paz-Diaz H, Shih JL, Davies JC.
Sawicki GS, et al. Among authors: paz diaz h.
J Cyst Fibros. 2022 Jul;21(4):675-683. doi: 10.1016/j.jcf.2022.02.003. Epub 2022 Feb 18.
J Cyst Fibros. 2022.
PMID: 35190292
Free article.
Clinical Trial.
Item in Clipboard
Long-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trial.
Flume PA, Harris RS, Paz-Diaz H, Ahluwalia N, Higgins M, Campbell D, Berhane I, Shih JL, Sawicki G.
Flume PA, et al. Among authors: paz diaz h.
J Cyst Fibros. 2023 May;22(3):464-470. doi: 10.1016/j.jcf.2022.12.006. Epub 2022 Dec 27.
J Cyst Fibros. 2023.
PMID: 36581484
Clinical Trial.
Item in Clipboard
Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD.
Vassaux C, Torre-Bouscoulet L, Zeineldine S, Cortopassi F, Paz-Díaz H, Celli BR, Pinto-Plata VM.
Vassaux C, et al. Among authors: paz diaz h.
Eur Respir J. 2008 Nov;32(5):1275-82. doi: 10.1183/09031936.00151707. Epub 2008 Jun 11.
Eur Respir J. 2008.
PMID: 18550609
Free article.
Item in Clipboard
Pulmonary rehabilitation improves depression, anxiety, dyspnea and health status in patients with COPD.
Paz-Díaz H, Montes de Oca M, López JM, Celli BR.
Paz-Díaz H, et al.
Am J Phys Med Rehabil. 2007 Jan;86(1):30-6. doi: 10.1097/phm.0b013e31802b8eca.
Am J Phys Med Rehabil. 2007.
PMID: 17304686
Clinical Trial.
Item in Clipboard
Cite
Cite